Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 8:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Relapse/Recurrence Clear all
Completed Phase 1 Interventional
View directory record Official record
Conditions
Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm, Refractory Malignant Neoplasm
Interventions
Anakinra, Denosumab, Everolimus
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced May 21, 2026, 8:59 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
busulfan, cyclosporine, fludarabine phosphate, mycophenolate mofetil, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Drug · Procedure
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 120 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 9, 2018 · Synced May 21, 2026, 8:59 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Lymphoma
Interventions
cryopreservation
Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2011
U.S. locations
82
States / cities
Anchorage, Alaska • Atlanta, Georgia • Austell, Georgia + 51 more
Source: ClinicalTrials.gov public record
Updated May 19, 2013 · Synced May 21, 2026, 8:59 PM EDT
Withdrawn Not applicable Interventional
View directory record Official record
Conditions
Obstructive Sleep Apnea, Atrial Fibrillation
Interventions
Cardiac Ablation for Atrial Fibrillation
Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated May 23, 2022 · Synced May 21, 2026, 8:59 PM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Neuroblastoma, Ovarian Cancer, Psychosocial Effects of Cancer and Its Treatment, Testicular Germ Cell Tumor
Interventions
psychosocial assessment and care
Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 20, 2010 · Synced May 21, 2026, 8:59 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Pediatric Solid Tumor, Sarcoma, Neuroblastoma, Wilms Tumor
Interventions
Not listed
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Up to 30 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
5
States / cities
San Francisco, California • Washington D.C., District of Columbia • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2015 · Synced May 21, 2026, 8:59 PM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Follicular Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Small Lymphocytic Lymphoma
Interventions
Laboratory Biomarker Analysis, Lenalidomide, Obinutuzumab
Other · Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2025 · Synced May 21, 2026, 8:59 PM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Not listed
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced May 21, 2026, 8:59 PM EDT
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
Maplirpacept, Tafasitamab, Lenalidomide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
Baton Rouge, Louisiana • Ann Arbor, Michigan • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced May 21, 2026, 8:59 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Prostate Cancer
Interventions
Control, Sipuleucel-T
Other · Biological
Lead sponsor
Dendreon
Industry
Eligibility
18 Years to 80 Years · Male only
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2015
U.S. locations
18
States / cities
Berkeley, California • Laguna Hills, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2018 · Synced May 21, 2026, 8:59 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Hepatic Complication
Interventions
Cisplatin, Gemcitabine Hydrochloride, Quality-of-Life Assessment, Sirolimus
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 20, 2016 · Synced May 21, 2026, 8:59 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Relapsed or Refractory Multiple Myeloma
Interventions
Dexamethasone, Carfilzomib
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
31
States / cities
Palm Springs, California • Riverside, California • Glenwood Springs, Colorado + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced May 21, 2026, 8:59 PM EDT
Terminated No phase listed Observational
View directory record Official record
Conditions
Diabetic Foot, Ulcer Foot
Interventions
no interventions
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 22, 2023 · Synced May 21, 2026, 8:59 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Endometrial Carcinoma
Interventions
Arsenic trioxide
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced May 21, 2026, 8:59 PM EDT
Completed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
carboplatin, docetaxel, ifosfamide, autologous bone marrow transplantation, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
Drug · Procedure
Lead sponsor
Cancer Treatment Centers of America
Other
Eligibility
Up to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Zion, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 25, 2013 · Synced May 21, 2026, 8:59 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Hodgkin Lymphoma, Relapsed or Refractory Hodgkin Lymphoma
Interventions
pembrolizumab, gemcitabine, vinorelbine, liposomal doxorubicin, Stem cell mobilization and collection
Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
10
States / cities
Duarte, California • Stanford, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced May 21, 2026, 8:59 PM EDT
Withdrawn Phase 3 Interventional
View directory record Official record
Conditions
Bladder Cancer
Interventions
Mycobacterial Cell-Wall DNA Complex, Bacillus Calmette-Guerin
Biological
Lead sponsor
Bioniche Life Sciences Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
14
States / cities
Laguna Hills, California • Los Angeles, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2014 · Synced May 21, 2026, 8:59 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Noncontiguous Stage II Small Lymphocytic Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Stage III Small Lymphocytic Lymphoma, Stage IV Small Lymphocytic Lymphoma
Interventions
apolizumab, laboratory biomarker analysis, pharmacological study
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
2
States / cities
La Jolla, California • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 15, 2013 · Synced May 21, 2026, 8:59 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Angioimmunoblastic T-cell Lymphoma, B-cell Childhood Acute Lymphoblastic Leukemia, B-cell Chronic Lymphocytic Leukemia, Childhood Burkitt Lymphoma, Childhood Diffuse Large Cell Lymphoma, Childhood Grade III Lymphomatoid Granulomatosis, Childhood Immunoblastic Large Cell Lymphoma, Childhood Nasal Type Extranodal NK/T-cell Lymphoma, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Small Intestine Lymphoma, T-cell Childhood Acute Lymphoblastic Leukemia, T-cell Large Granular Lymphocyte Leukemia, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
oxaliplatin, etoposide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 23, 2014 · Synced May 21, 2026, 8:59 PM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
nelarabine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
7
States / cities
Duarte, California • Tampa, Florida • Bethesda, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced May 21, 2026, 8:59 PM EDT
Completed No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Cytomegalovirus Infections, Cytomegalovirus Retinitis, Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
16
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2008 · Synced May 21, 2026, 8:59 PM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Relapse/Refractory Multiple Myeloma
Interventions
CYAD-211, Endoxan, Fludara
Biological · Drug
Lead sponsor
Celyad Oncology SA
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2037
U.S. locations
2
States / cities
Tampa, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced May 21, 2026, 8:59 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Relapsed or Refractory Medulloblastoma (MB), Neuroblastoma (NB), Ewing Sarcoma (ES) and Alveolar Rhabdomyosarcoma (ARMS)
Interventions
TB-403 20mg/kg, TB-403 50mg/kg, TB-403 100mg/kg, TB-403 175mg/kg
Drug
Lead sponsor
Oncurious NV
Industry
Eligibility
6 Months to 18 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
10
States / cities
Little Rock, Arkansas • Oakland, California • Hartford, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced May 21, 2026, 8:59 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
polifeprosan 20 with carmustine implant, surgical procedure, iodine I 125
Drug · Procedure · Radiation
Lead sponsor
Barrett Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 25, 2013 · Synced May 21, 2026, 8:59 PM EDT